Global Glaucoma Market Projected to Expand at 5.4% CAGR by 2029

Unlock Global Insights – Save 20% on Market Reports with Code ONLINE20

How Much Larger Is The Glaucoma Market Expected To Become By 2029 Compared With Its 2025 Level?

The size of the glaucoma market has experienced robust growth in recent years. It is anticipated to expand from $7.76 billion in 2024 to $8.2 billion in 2025, reflecting a compound annual growth rate (CAGR) of 5.6%. The historical growth can be linked to heightened awareness of eye health, increased healthcare spending, the rising adoption of telemedicine for eye care, expanding healthcare infrastructure, and an uptick in government healthcare initiatives.

The glaucoma market is projected to experience substantial expansion over the upcoming years. Its valuation is anticipated to reach $10.12 billion by 2029, exhibiting a compound annual growth rate (CAGR) of 5.4%. This projected growth throughout the forecast period stems from factors such as an aging population, increasing incidence of glaucoma, a growing preference for minimally invasive surgical procedures, and the rising prevalence of both diabetes and hypertension. Key developments anticipated during this period encompass enhancements in diagnostic tools, the introduction of novel pharmaceutical treatments, technological progress in surgical equipment, the availability of combined therapeutic approaches, and the increasing adoption of robotic surgeries.

Unlock Your Free Sample Report for Exclusive Market Data:

https://www.thebusinessresearchcompany.com/sample.aspx?id=20820&type=smp

Which Factors And Drivers Are Influencing The Glaucoma Market In 2025?

An increasing incidence of chronic eye ailments is anticipated to stimulate the expansion of the glaucoma market in the coming years. These long-term disorders affect the eyes, frequently causing ongoing visual impairment or discomfort and requiring continuous management or treatment. The growth in chronic eye conditions can be attributed to an aging populace, increased screen usage, lifestyle factors, and a higher occurrence of conditions like diabetes and hypertension. Glaucoma treatment is essential for chronic eye conditions to reduce intraocular pressure, prevent further damage to the optic nerve, and preserve vision, as untreated glaucoma can lead to irreversible blindness. For instance, in December 2024, data from the National Health Service (NHS), the UK-based publicly funded healthcare system, revealed that over 2 million individuals in the UK were living with sight loss in 2024. Furthermore, projections indicate that the number of people experiencing sight loss will rise by 27%, reaching approximately 2.8 million by 2035. Thus, the growing prevalence of chronic eye conditions is a significant driver for the glaucoma market.

Which Key Segments Fueling The Glaucoma Market?

The glaucomamarket covered in this report is segmented –

1) By Disease Type: Open Angle Glaucoma; Angle Closure Glaucoma; Other Disease Types

2) By Diagnosis: Tonometry; Ophthalmoscopy; Perimetry; Gonioscopy

3) By Drug Class: Beta Blockers; Prostaglandins; Alpha Adrenergic Agonist; Carbonic Anhydrase Inhibitors; Combination Drugs; Other Drug Classes

4) By Administration: Oral; Injections; Intravitreal; Other Administrations

5) By End-User: Hospitals; Ophthalmic Clinics; Ambulatory Surgical Centers

Subsegments:

1) By Open Angle Glaucoma: Primary Open Angle Glaucoma (POAG); Secondary Open Angle Glaucoma

2) By Angle Closure Glaucoma: Primary Angle Closure Glaucoma; Secondary Angle Closure Glaucoma

3) By Other Disease Types: Normal-Tension Glaucoma; Pigmentary Glaucoma; Pseudoexfoliative Glaucoma; Congenital Glaucoma

What Key Innovation Trends Are Fueling Advancements In The Glaucoma Market?

Leading companies in the glaucoma market are concentrating on developing innovative therapies, such as Rho-kinase (ROCK) inhibitors. These aim to provide a dual mechanism of action, effectively reducing intraocular pressure by both enhancing aqueous humor outflow and relaxing trabecular meshwork cells, making them potent in treating glaucoma. Rho-kinase (ROCK) inhibitors constitute a class of drugs that specifically target and inhibit the activity of Rho-kinase enzymes, which are responsible for regulating cell contraction and are used to treat glaucoma by lowering intraocular pressure. For example, in July 2023, Santen Pharmaceutical Co. Ltd., a Japan-based eye care products company, launched Roclanda in the UK. Roclanda is a fixed-dose combination (FDC) of latanoprost and netarsudil, which is a novel Rho-kinase (ROCK) inhibitor, and it effectively reduces intraocular pressure (IOP) by addressing trabecular meshwork dysfunction. It is indicated for adult patients with primary open-angle glaucoma or ocular hypertension who have not achieved adequate IOP reduction with monotherapy using a prostaglandin or netarsudil. The introduction of Roclanda in Europe signifies the first new class of glaucoma medication in 25 years, offering a significant breakthrough in treatment. By combining netarsudil and latanoprost, Roclanda operates synergistically to increase outflow through both trabecular (conventional) and uveoscleral (unconventional) pathways, thereby providing a comprehensive strategy for managing elevated IOP.

Which Major Firms Are Strengthening Their Position In The Glaucoma Industry?

Major companies operating in the glaucoma market are Roche Holding AG, Merck & Co. Inc., AbbVie Inc., Novartis AG, Teva Pharmaceuticals Industries Ltd., Otsuka Pharmaceutical Co. Ltd., Sun Pharmaceutical Industries Ltd., Cipla Limited, Bausch & Lomb Corp., Carl Zeiss Meditec, Santen Pharmaceuticals Co. Ltd., Topcon Corporation, Thea Laboratoires, Corza Ophthalmology, Lumenis Ltd., Alcon Inc., Viva BioInnovator, Glaukos Corporation, Iridex Corporation, Nova Eye Medical Ltd., Renova Life Sciences Private Limited, Qlaris Bio Inc., PolyActiva Pty Ltd., Nidek Co. Ltd., Haag-Streit AG

Download The Full Report For Exclusive Market Findings:

https://www.thebusinessresearchcompany.com/report/glaucoma-global-market-report

Which Region Is Projected To Lead The Glaucoma Market During The Forecast Period?

North America was the largest region in the glaucoma market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the glaucoma market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Version Of The Glaucoma Market Report:

https://www.thebusinessresearchcompany.com/customise?id=20820&type=smp

Browse Through More Reports Similar to the Global Glaucoma Market 2025, By The Business Research Company

Antiglaucoma Drugs Market 2025

https://www.thebusinessresearchcompany.com/report/antiglaucoma-drugs-market

Antiglaucoma Drugs Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/antiglaucoma-drugs-global-market-report

Glaucoma Surgery Devices Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/glaucoma-surgery-devices-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795